SHORT-TERM EFFECTS OF CALCIUM-ANTAGONISTS ON HEMODYNAMICS AND CYCLOSPORINE PHARMACOKINETICS IN HEART-TRANSPLANT AND KIDNEY-TRANSPLANT PATIENTS

被引：16
作者：
ROY, LF
EAST, DS
BROWNING, FM
SHAW, D
OGILVIE, RI
CARDELLA, C
LEENEN, FHH
机构：
[1] TORONTO WESTERN HOSP,DEPT MED,DIV CLIN PHARMACOL,TORONTO M5T 2S8,ONTARIO,CANADA
[2] TORONTO WESTERN HOSP,DEPT MED,DIV NEPHROL,TORONTO M5T 2S8,ONTARIO,CANADA
[3] UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA
[4] UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A1,ONTARIO,CANADA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1989年 / 46卷 / 06期
关键词：
D O I：
10.1038/clpt.1989.202
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：657 / 667
页数：11
相关论文
共 50 条
[21]   Low incidence of malignancy in heart-transplant recipients in Taiwan: an update and comparison with kidney-transplant recipients [J].
Hsu, Ron-Bin ;
Chang, Chung-I ;
Tsai, Meng-Kun ;
Lee, Po-Huang ;
Chou, Nai-Kuan ;
Chi, Nai-Hsin ;
Wang, Shoei-Shen ;
Chu, Shu-Hsun .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2010, 37 (05) :1117-1121
[22]   INTRAVENOUS ADMINISTRATION OF CYCLOSPORINE FOR IMMUNOSUPPRESSION IN HEART-TRANSPLANT PATIENTS [J].
MACRIS, MP ;
FRAZIER, OH ;
VANBUREN, CT ;
LAMMERMEIER, DE ;
SWEENEY, MS ;
KAHAN, BD .
TRANSPLANTATION PROCEEDINGS, 1989, 21 (01) :2487-2487
[23]   INTERACTION BETWEEN ROXITHROMYCIN AND CYCLOSPORINE IN HEART-TRANSPLANT PATIENTS [J].
BILLAUD, EM ;
GUILLEMAIN, R ;
FORTINEAU, N ;
KITZIS, MD ;
DREYFUS, G ;
AMREIN, C ;
KREFTJAIS, C ;
HUSSON, JM ;
CHRETIEN, P .
CLINICAL PHARMACOKINETICS, 1990, 19 (06) :499-502
[24]   A COMPARISON OF THE EFFECTS OF RAPAMYCIN AND CYCLOSPORINE ON KIDNEY AND HEART MORPHOLOGY IN A RABBIT HETEROTOPIC HEART-TRANSPLANT MODEL [J].
THLIVERIS, JA ;
SOLEZ, K ;
YATSCOFF, RW .
HISTOLOGY AND HISTOPATHOLOGY, 1995, 10 (02) :417-421
[25]   AZATHIOPRINE (AZA) BIOAVAILABILITY AND PHARMACOKINETICS IN KIDNEY-TRANSPLANT PATIENTS [J].
DING, TL ;
GAMBERTOGLIO, JG ;
AMEND, WJC ;
BIRNBAUM, J ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (02) :250-250
[26]   PHARMACOKINETICS OF METHYLPREDNISOLONE AND REJECTION EPISODES IN KIDNEY-TRANSPLANT PATIENTS [J].
KELLER, F ;
HEMMEN, T ;
SCHONESHOFER, M ;
SCHWARZ, A ;
OFFERMANN, G .
TRANSPLANTATION, 1995, 60 (04) :330-333
[27]   Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A [J].
Park, JW ;
Siekmeier, R ;
Merz, M ;
Krell, B ;
Harder, S ;
März, W ;
Seidel, D ;
Schüler, S ;
Gross, W .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2002, 40 (10) :439-450
[28]   EFFECT OF ERYTHROMYCIN ON BLOOD CYCLOSPORINE CONCENTRATIONS IN KIDNEY-TRANSPLANT PATIENTS [J].
BENARI, J ;
EISENSTEIN, B ;
DAVIDOVITS, M ;
SHMUELI, D ;
SHAPIRA, Z ;
STARK, H .
JOURNAL OF PEDIATRICS, 1988, 112 (06) :992-993
[29]   COMPARISON OF 4 DIFFERENT CYCLOSPORINE IMMUNOASSAYS IN HEART AND KIDNEY-TRANSPLANT RECIPIENTS [J].
HESSE, CJ ;
BAAN, CC ;
DAANE, R ;
STOLK, BJM ;
JUTTE, NHPM ;
HENDRIKS, GFJ ;
WEIMAR, W .
THERAPEUTIC DRUG MONITORING, 1990, 12 (06) :547-553
[30]   EFFECT OF DIETARY-FAT ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF CYCLOSPORINE IN KIDNEY-TRANSPLANT RECIPIENTS [J].
TAN, KKC ;
TRULL, AK ;
UTTRIDGE, JA ;
METCALFE, S ;
HEYES, CS ;
FACEY, S ;
EVANS, DB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (04) :425-433
12345